Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Experimental procedures br Results
2024-03-22

Experimental procedures Results Discussion Acknowledgments SRE and EBL contributed equally to this SZL P1-41 work. SRE, EBL, and MJT designed experiments, SRE, EBL, MCH, and AEI conducted experiments, SRE and EBL analyzed data, and EBL and MJT wrote the manuscript. We would like to than
-
br STAR Methods br Author Contributions br Acknowledgments
2024-03-22

STAR★Methods Author Contributions Acknowledgments This study is funded by National Institutes of Health (NIH) Grants NS028901 and DC004450 (to L.O.T.); N.L. Tartar Trust Fellowship (to H.-W.L.); DC014878 to T.S.B. We thank members of the Trussell lab for helpful discussions, Dr. Stephen Dav
-
Based on our findings in this work
2024-03-22

Based on our findings in this work as well as the previous published data in the experimental mice model of RSV infection, we suggest that modulation of 12/15 LOX expression and/or blocking of LOX products such as 12(S)-HETE may represent potential pharmacological approaches to prevent or treat vira
-
An important observation is that this patient has
2024-03-22

An important observation is that this patient has been on ALK inhibitor for more than 4 years (51 months: 27 months on crizotinib+24 months on alectinib and on-going) and there was no evidence of disease progression in the central nervous system. The other potential driver mutation in this patient’s
-
5046 In particular we focused our
2024-03-21

In particular, we focused our attention on beta2 adrenergic receptors, since their commercial inhibitors are effective in lowering IOP, the primary indication of glaucoma. The hypotensive action of a commercial sequence of beta2 adrenergic receptor siRNA was tested in rabbits. The results confirmed
-
Oxidative stress has recently been reported as one
2024-03-21

Oxidative stress has recently been reported as one of the important mechanisms of toxic effect of Cd2+[43]. The mechanism of Cd2+-induced oxidative stress involves an imbalance between generation and removal of ROS in tissues and cellular components, causing damage to membranes, DNA, and proteins [4
-
The geometry of two three four and
2024-03-21

The geometry of two, three, four and five KT 5823 mg neutral radical ACh molecule complexes with various electronic configurations, i.e. with various multiplicities equal to 1, 2 and 4 (for ACh trimer) were determined using DFT with the unrestricted B97d/SVP potential/basis set in Gaussian09 program
-
br Introduction Nausea and vomiting are among the
2024-03-21

Introduction Nausea and vomiting are among the most distressing side effects associated with chemotherapy in cancer patients (Billio et al., 2010). Severe emesis can negatively affect a patient's nutritional state, ability to work and motivation, which can, in turn, interfere with the clinical co
-
br Conclusion Growth survival and invasion
2024-03-21

Conclusion Growth, survival, and invasion of most PCs have been shown to be androgen-dependent at the onset of castration therapy [31]. Thus, castration therapy has been central to systemic therapy and remains the standard approach to PC treatment. Even after progression to a castration-resistant
-
Screening a selection of analogues from this library against
2024-03-21

Screening a selection of analogues from this library against the panel of 26 kinases (16, 22, and 24 were screened at 30 μM due to poor solubility; 17 tested at 100 μM) generally demonstrated an increase in activity compared to Captopril 3 (Fig. 3, Fig. 6). The benzamide analogue 16 demonstrated >5
-
br Perspective AA LA and other PUFAs and their lipid
2024-03-21

Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path
-
In vascular endothelial cells L arginine produces nitric oxi
2024-03-21

In vascular endothelial cells, L-arginine produces nitric oxide (NO) under the action of nitric oxide synthase (NOS), and nitric oxide can activate guanylate cyclase to produce a large amount of cGMP, thereby relaxing vascular smooth muscle and expanding blood vessels. Numerous studies have confirm
-
Inflammations lead to the perturbation of aromatase enzyme w
2024-03-21

Inflammations lead to the perturbation of aromatase enzyme [112], which normally is responsible for a broad array of critical functions. Chemotherapy targets this enzyme, so this treatment option is never side-effect-free and not fully-effective. Therefore, the mankind should be careful so as not to
-
br Current limitations and future directions There are sever
2024-03-21

Current limitations and future directions There are several limitations associated with PET imaging of aromatase using carbon-11 labeled aromatase inhibitors. Due to the very short half-life of carbon 11 (20min), PET studies with currently available, validated tracers can only be performed in med
-
ARG I is one of the most
2024-03-21

ARG I is one of the most important mammalian enzymes responsible for nitrogen metabolism since it comprises the main route for the elimination of excess nitrogen resulting from amino 366 2 mg and nucleotide metabolism [18]. ARG I deficiency leads to hyperargininemia, characterized by progressive neu
15737 records 180/1050 page Previous Next First page 上5页 176177178179180 下5页 Last page